Drug-drug interaction study of dapagliflozin with Voglibose in Japanese type 2 diabetes mellitus patients

Study identifier:D1692C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Multi-centre, Drug-drug Interaction Study to assess the effect of Voglibose (0.2 mg tid) on the Pharmacokinetics, Safety and Tolerability of single oral administration of dapagliflozin (10 mg) in Japanese Patients with Type 2 Diabetes

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

No

Study drug

Dapagliflozin

Sex

All

Actual Enrollment

28

Study type

Interventional

Age

20 Years +

Date

Study Start Date: 01 Jan 2010
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010

Study design

Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria